Zai Lab (ZLAB) stock is back in focus after China’s National Medical Products Administration approved TIVDAK for recurrent or metastatic cervical cancer, following positive Phase 3 data and prior approvals in the US, EU, Japan, and other regions.

Despite the TIVDAK approval, Zai Lab’s share price has been under pressure, with a 30 day share price return down 11.4% and a 1 year total shareholder return down 56.5%, pointing to weak momentum even as new products reach the market.

If you are looking beyond a single stock and want to see what else is moving in healthcare AI, it can be useful to scan 39 healthcare AI stocks.

With TIVDAK now cleared in China and the stock down sharply over 1 and 5 years, investors are left weighing the gap between Zai Lab’s pipeline potential and its current US$16.48 share price. Is this a reset entry point, or is the market already factoring in future growth?

Most Popular Narrative: 51.2% Undervalued

At a last close of $16.48 versus a narrative fair value of $33.78, the current pricing sits well below what the most followed valuation framework suggests.

Multiple high-potential product launches and label expansions over the next 12 to 18 months, including VYVGART, bemarituzumab, KarXT, TIVDAK, and Tumor Treating Fields, combined with a deep pipeline in oncology and immunology, are expected to significantly increase Zai Lab's addressable market and diversify revenue streams, supporting both top-line growth and future earnings.

Curious what kind of revenue curve and margin reset could support that gap between today’s price and the fair value line? The core assumptions blend fast top line expansion, improving profitability and a future earnings multiple that is usually reserved for higher growth peers.

Result: Fair Value of $33.78 (UNDERVALUED)

However, investors still need to keep an eye on competitive pressure in oncology and immunology, as well as on China pricing or reimbursement shifts that could squeeze margins.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment clearly split between concern and optimism, it makes sense to move quickly and check the details yourself before views harden around the stock. Start by reviewing the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Zai Lab is on your radar, do not stop there. Broaden your watchlist now so you are not chasing the next opportunity after it has already moved.

• Scan 23 elite penny stocks with strong financials to identify potential high growth stories while prices are still in the lower range.
• Review the 47 high quality undervalued stocks to focus on quality at a discount before other investors catch on.
• Consider companies in the 62 resilient stocks with low risk scores if you want to emphasize resilience within a cautious playbook.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.